NPHLA Daily
NPHLA Daily
Wednesday, October 14, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
Clinical trial phases, explained: what phase 1, 2, 3 and 4 tell you
FDA describes four phases of clinical research: phase 1 focuses on safety and dosage, phase 2 on efficacy and side effects, phase 3 on efficacy and monitoring of adverse reactions in larger groups, and phase 4 on safety and efficacy after approval.
Metabolic signal
What changed today in Metabolic: 3 trial updates, 2 new studies
NPHLA tracked 5 new official records on this desk today: 2 new studies, 3 trial updates. First: New research in Hormone research in paediatrics: “Weight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case…
Regulatory signal
What PBM reform proposals would change for pharmacies
PBMs manage prescription drug benefits for insurers, Medicare Part D plans and employers. Reform proposals target spread pricing, how PBMs are compensated and what they must disclose; for Part D pharmacies, price concessions have been applied at the point of sale since January…
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 3 new studies, 1 trial update
NPHLA tracked 4 new official records on this desk today: 3 new studies, 1 trial update. First: New research in Clinics in dermatology: “Cutaneous Effects and Aesthetic Management of Glucagon-like Peptide-1 Receptor Agonists: A Narrative Review”.
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- FDA describes four phases of clinical research: phase 1 focuses on safety and dosage, phase 2 on efficacy and side effects, phase 3 on efficacy and monitoring of adverse reactions in larger groups, and phase 4 on…
- PBMs manage prescription drug benefits for insurers, Medicare Part D plans and employers. Reform proposals target spread pricing, how PBMs are compensated and what they must disclose; for Part D pharmacies, price…
- A drug on FDA’s drug shortage list is not treated as commercially available for the section 503A copies limit, and outsourcing facilities may compound copies of an approved drug while it is on the list — flexibilities…
- Federal law recognizes two compounding pathways: section 503A, for state-licensed pharmacies and physicians compounding for identified patients, and section 503B, for registered outsourcing facilities that must meet…
- What changed today in Metabolic: 3 trial updates, 2 new studies
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.